Protect Your Investments with Operational Diligence

You back great science and strong teams. Concordia makes sure the operational plan underneath can deliver what the capital depends on.

Every engagement begins with a Portfolio Insight Intensive to evaluate the operational plan, and identify how we can best support you throughout. 

Decorative pattern of hexagons connected by swirls and lines in shades of brown and beige on a black background.
Macro photograph of water droplets and air bubbles forming intricate cellular patterns.

Get Full Visibility Into Whether the Plan Can Deliver what the Science Promises.

Clinical execution risk is difficult to evaluate from the outside. Sure, timelines look credible and the CRO’s plans are assembled. But will the assumptions hold when execution begins?

These are the gaps that erode your investment:

  • Enrollment estimates are often inherited rather than independently validated. 

  • Budget buffers may be thinner than they appear. 

  • CROs are sometimes selected to maintain momentum rather than because the program was fully ready for that model. 

  • And timelines are frequently baked into investor decks before contracts are finalized.

When these happen, burn extends, inflection points shift, and follow-on rounds become stabilization rounds instead of value-creation rounds.

We’ll catch these leaks early so that your funds have more impact in less time.

Hands cradling a copper mug over printed charts and reports.

Add Confidence To Your Portfolio.

Diligence that includes execution reality.

clinical_notes

Grounded in actual enrollment behavior and site capacity, not inherited projections that require best-case execution.

app_registration

Fewer surprises in portfolio reviews.

Assumptions challenged before contracts are signed, not discovered after margin is already committed.

Clearer decisions

Walk into investor and board meetings knowing what's solid, what's being watched, and what you'd do if something shifts.

gavel

The Concordia Difference: Risk mitigation with smarter operations.

We’re built for how investors make decisions:

Close-up of two people shaking hands in a professional setting.
Detail of classical Ionic columns and ornate cornice against a warm sky.
Overhead view of two women in blazers collaborating over documents at a table. Patient-Centered Results
Focused on capital allocation.
Our assessments are designed for your investment committee, not a clinical operations meeting. We make these easy to understand in terms of time realism, burn exposure, and milestone durability. Feasible by Design
Grounded in operational excellence.
Management teams represent operational risk as best as they can. But if the team is strong scientifically rather than operationally, blind spots persist. We know where to focus our efforts because we’ve been the ones discovering mid-study leaks before. Operator-Led
Visibility for everyone.
You don’t have the capacity to micromanage, yet don’t want to wait until operations falter to step in. We prevent surprises with independent reviews that give both investors and management a shared view of operational reality. Modular & Right-Sized

FOUNDER AND PRINCIPAL


Suzanne Vyvoda

Suzanne in a burgundy blazer and cream blouse smiling confidently while walking through an arched outdoor corridor.

Suzanne is a senior clinical operations leader with 20+ years of experience guiding global development programs for emerging biotechs and large pharmaceutical organizations. Her work spans more than 50 countries and 500+ clinical research sites across multiple therapeutic areas and stages of development.

Beginning her career at research sites and CROs, she brings a rare 360° perspective on how decisions flow, where systems break down, and what operational excellence truly requires. Her approach blends strategy, operational design, and real-world execution—helping programs move with clarity, alignment, and control.

WORK WITH US

  Start with a Portfolio Insight Intensive

A two-week, senior-level engagement for VCs, operating partners, and investment committees. 

Get a rapid, independent view of operational reality before allocating additional capital or signing off on a major commitment. Over two weeks, we review clinical or development programs, vendor relationships, enrollment feasibility, timelines, and execution capabilities to identify risks, misaligned incentives, or gaps that could compromise value creation. 

You’ll receive an executive memo detailing high-risk areas, actionable recommendations, capital implications, and a 60-minute walkthrough with investment team.

After your intensive, we offer two right-sized ways to continue working together:

Venture Advisory Retainer

Ongoing strategic access for diligence calls, operational pressure-testing, and executive advising across your clinical-stage portfolio.

Portfolio Acceleration Engagement

Hands-on support embedded within a portfolio company to align clinical strategy with execution — so promising assets move forward on plan.